Ruffer LLP’s Catalyst Pharmaceutical CPRX Stock Holding History

Ruffer LLP’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-70,807	Closed	-$1.66M	–	194
2025 Q4	$1.66M	Sell	70,807 -37,809	-35%	-$842K	0.08%	128
2025 Q3	$2.14M	Buy	+108,616	New	+$2.23M	0.12%	86

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ruffer LLP's CPRX Position: Q1 2026 in Review

Ruffer LLP sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 70,807 shares — an estimated $1.66M sold.

Ruffer LLP first reported a position in CPRX in Q3 2025 and held it in 2 quarters. The position peaked at $2.14M in Q3 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Ruffer LLP reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Ruffer LLP sold 70,807 Catalyst Pharmaceutical shares in Q1 2026, an estimated $1.66M.
Ruffer LLP first reported a position in Catalyst Pharmaceutical in Q3 2025 and held it in 2 quarters.
Ruffer LLP's Catalyst Pharmaceutical position peaked at $2.14M in Q3 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Ruffer LLP's 13F filing for Q1 2026, filed 13 May 2026.